Advanced search
Publication Cover
Clinical, Cosmetic and Investigational Dermatology Volume 17, 2024 - Issue
Submit an article Journal homepage
21
Views
0
CrossRef citations to date
0
Altmetric
CASE SERIES

Anti-Interleukin 17A Biologic Therapy Attempts on Livedoid Vasculopathy: A Report of Case Series

Fei QiDepartment of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, 100730, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-5364-4235View further author information
ORCID Icon,
Yimeng GaoDepartment of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, 100730, People’s Republic of ChinaView further author information
&
Hongzhong JinDepartment of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, 100730, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 1043-1048 | Received 31 Jan 2024, Accepted 15 Apr 2024, Published online: 08 May 2024

References

  • Zhao C, Jing K, Feng S. Clinical analysis of skin lesions in livedoid vasculopathy: a study of 46 Chinese patients. Int J Dermatol. 2023;62(2):212–216. doi:10.1111/ijd.16477
  • Eswaran H, Googe P, Vedak P, Marston WA, Moll S. Livedoid vasculopathy: a review with focus on terminology and pathogenesis. Vasc Med. 2022;27(6):593–603. doi:10.1177/1358863X221130380
  • Gao Y, Jin H. Livedoid vasculopathy and peripheral neuropathy: a retrospective cohort study of 55 Chinese patients and literature review. Int Wound J. 2023;20(5):1498–1505. doi:10.1111/iwj.14004
  • Micieli R, Alavi A. Treatment for livedoid vasculopathy: a systematic review. JAMA Dermatol. 2018;154(2):193–202. doi:10.1001/jamadermatol.2017.4374
  • Gao Y, Jin H. Real-world data on pain management and effectiveness of anti-tumour necrosis factor agents in refractory livedoid vasculopathy. J Eur Acad Dermatol Venereol. 2022;36(1):e46–e48. doi:10.1111/jdv.17613
  • Daniele SG, Eldirany SA, Damiani G, Ho M, Bunick CG. Structural basis for p19 targeting by anti-IL-23 biologics: correlations with short- and long-term efficacy in psoriasis. JID Innov. 2024;4(2):100261. doi:10.1016/j.xjidi.2024.100261
  • Bilgic A, Ozcobanoglu S, Bozca BC, Alpsoy E. Livedoid vasculopathy: a multidisciplinary clinical approach to diagnosis and management. Int J Women's Dermatol. 2021;7(5 Part A):588–599. doi:10.1016/j.ijwd.2021.08.013
  • Gao Y, Jin H. Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis. J DermatolTreat. 2022;33(1):178–183. doi:10.1080/09546634.2020.1737634
  • Sarkar S, Panda S, Kim B, Raychaudhuri SK, Ghosh A, Raychaudhuri SP. Risk of tuberculosis with anti-tumor necrosis factor-alpha therapy in patients with psoriasis and psoriatic arthritis in Indian population. Indian J Dermatol Venereol Leprol. 2020;86(1):1–7. doi:10.4103/ijdvl.IJDVL_791_18
  • Han Y, Tu P. Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy. Front Immunol. 2022;13:1008392. doi:10.3389/fimmu.2022.1008392
  • Song X, Tu P. Treatment of Livedoid Vasculopathy With Baricitinib. JAMA Dermatol. 2022;158(5):587–589. doi:10.1001/jamadermatol.2022.0241
  • Mills KHG. IL-17 and IL-17-producing cells in protection versus pathology. Nat Rev Immunol. 2023;23(1):38–54. doi:10.1038/s41577-022-00746-9
  • Ruiz de Morales JMG, Puig L, Dauden E, et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: an updated review of the evidence focusing in controversies. Autoimmun Rev. 2020;19(1):102429. doi:10.1016/j.autrev.2019.102429
  • Damiani G, Radaeli A, Olivini A, Calvara-Pinton P, Malerba M. Increased airway inflammation in patients with psoriasis. Br J Dermatol. 2016;175(4):797–799. doi:10.1111/bjd.14546
  • von Stebut E, Reich K, Thaci D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol. 2019;139(5):1054–1062. doi:10.1016/j.jid.2018.10.042
  • Gelfand JM, Shin DB, Duffin KC, et al. A randomized placebo-controlled trial of secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S). J Invest Dermatol. 2020;140(9):1784–1793 e2. doi:10.1016/j.jid.2020.01.025
  • Bragazzi NL, Sellami M, Salem I, et al. Fasting and its impact on skin anatomy, physiology, and physiopathology: a comprehensive review of the literature. Nutrients. 2019;11(2). doi:10.3390/nu11020249
  • Damiani G, Pacifico A, Scoditti E, et al. Circadian oscillations of Minimal Erythema Dose (MED) are also influenced by diet in patients with psoriasis: a chronomedical study. Dermatol Ther. 2023;13(10):2229–2246. doi:10.1007/s13555-023-00987-z
  • Damiani G, Allocco F, Young dermatologists italian N, Malagoli P. COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers. Clin Exp Dermatol. 2021;46(6):1106–1108. doi:10.1111/ced.14631

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.